pyrazines has been researched along with Mesothelioma in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J | 1 |
| De Koning, L; De Wolf, J; Jaurand, MC; Jean, D; Le Pimpec-Barthes, F; Meiller, C; Montagne, F; Quetel, L; Tranchant, R; Zucman-Rossi, J | 1 |
| Aerts, JGJV; Baas, P; Cedrés, S; Fennell, DA; Gilligan, D; Kindler, H; Nakano, T; Nolan, L; Nowak, AK; Pachter, JA; Pavlakis, N; Scherpereel, A; Taylor, P; van Meerbeeck, JP; Weaver, DT | 1 |
| Aerts, JGJV; Baas, P; Fennell, DA; Gilligan, D; Kindler, H; Nakano, T; Nowak, AK; Pavlakis, N; Scherpereel, A; Taylor, P; van Meerbeeck, JP | 1 |
| Ishiki, H; Kiuchi, D; Masuda, K; Oyamada, S; Satomi, E; Shimizu, M | 1 |
| Arthur, K; Barbone, D; Broaddus, VC; Busacca, S; Chacko, AD; El-Tanani, M; Fennell, DA; Gaudino, G; Gorski, JJ; Gunasekharan, VK; Klabatsa, A; Mutti, L; Sheaff, M | 1 |
| Baas, P; Cufer, T; Danson, S; Gaafar, RM; Grossi, F; Hasan, B; O'Brien, ME; Ottensmeier, C; Pallis, A; Popat, S; Price, A; Talbot, DC; Van Meerbeeck, JP | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Dobra, K; Hjerpe, A | 1 |
| Dou, QP; Lonardo, F; Pass, HI; Puliyappadamba, VT; Rishi, AK; Ruckdeschel, JC; Sharma, S; Tarca, A; Wali, A; Wang, Y; Yang, H | 1 |
| Cao, X; Cui, Y; Littlejohn, JE; Peddaboina, C; Smythe, WR; Zhang, L | 1 |
| Baas, P; Busacca, S; Cakana, A; Donnellan, P; Fennell, DA; McCaffrey, J; McDowell, C; Meerbeeck, JV; Moulton, B; O'Byrne, KJ; Webb, G | 1 |
| Barbone, D; Battula, S; Broaddus, VC; Bueno, R; Busacca, S; Cheung, P; Fennell, DA; Gray, SG; Longley, DB; Sugarbaker, DJ | 1 |
| Bueno, R; Gordon, GJ; Kindler, HL; Mani, M; Maulik, G; Mukhopadhyay, L; Salgia, R; Sugarbaker, DJ; Yeap, BY | 1 |
| Barbone, D; Darnowski, JW; Fennell, DA; Galvani, A; Gasparri, F; Gaudino, G; Mutti, L; Nici, L; Porta, C; Sartore-Bianchi, A | 1 |
3 trial(s) available for pyrazines and Mesothelioma
| Article | Year |
|---|---|
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Diarrhea; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nausea; Neurofibromin 2; Pleural Neoplasms; Pyrazines; Sulfonamides; Treatment Outcome | 2019 |
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prospective Studies; Pyrazines; Time Factors; Treatment Outcome; Young Adult | 2013 |
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
Topics: Aged; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survival Rate | 2012 |
12 other study(ies) available for pyrazines and Mesothelioma
| Article | Year |
|---|---|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones | 2018 |
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Phenols; Pleural Neoplasms; Pyrazines; Quinolones; RNA Interference; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Verteporfin | 2018 |
Reply to K. Masuda et al.
Topics: Benzamides; Double-Blind Method; Humans; Mesothelioma; Neurofibromin 2; Pyrazines; Sulfonamides | 2019 |
Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.
Topics: Benzamides; Double-Blind Method; Humans; Mesothelioma; Neurofibromin 2; Pleural Neoplasms; Pyrazines; Sulfonamides | 2019 |
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Mesothelioma; Mice; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Transcription, Genetic | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Targeted therapy--possible new therapeutic option for malignant mesothelioma?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Humans; Mesothelioma; Oligosaccharides; Proteasome Endopeptidase Complex; Proteoglycans; Pyrazines; Sodium Selenite; Thioredoxins | 2008 |
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; Flow Cytometry; Humans; Mesothelioma; Pilot Projects; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Time Factors | 2010 |
Characterization of bortezomib-adapted I-45 mesothelioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Mesothelioma; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcription Factor CHOP; Transfection; Unfolded Protein Response | 2010 |
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spheroids, Cellular; Up-Regulation; Vorinostat | 2012 |
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genes, Intracisternal A-Particle; Glutamates; Guanine; Humans; Mesothelioma; Neoplasm Proteins; Pemetrexed; Pleural Neoplasms; Proteasome Inhibitors; Pyrazines; Survival Analysis | 2008 |
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Male; Mesothelioma; Mice; Mice, Nude; NF-kappa B; Nitriles; Proteasome Inhibitors; Pyrazines; Sulfones; Tumor Necrosis Factor-alpha | 2007 |